Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 543 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is B  [Clear All Filters]
2026
Hunt DM, Pisco JPedro, Rodgers A, de Chiara C, Zaveri A, Pacholarz KL, Evangelopoulos D, Garza-Garcia A, Ehrt S, Schnappinger D et al..  2026.  Activation of L-histidine biosynthesis as a new antibiotic strategy against Mycobacterium tuberculosis.. Nat Commun. 17(1)
Warrier T, Martinez-Hoyos M, de Francisco EPorras, Lenaerts AJ, Gruppo V, Robertson GT, Li K, Aubé J, Bonnet I, Jiang X et al..  2026.  Diaryl-Aminoindazole with Extensive In Vitro Mycobactericidal Activity Dependent on Exposure to Reactive Nitrogen Species.. ACS Infect Dis.
Aguilera-Diaz A, Feinberg PB, Huang J, Spier E, Barany F, Bacolod MD.  2026.  Establishment and Performance Evaluation of a Multiplexed TET2-APOBEC-Mediated cfDNA Methylation Detection Workflow Using qPCR and dPCR Readouts.. J Pers Med. 16(5)
Aguilera-Diaz A, Feinberg PB, Huang J, Spier E, Barany F, Bacolod MD.  2026.  Establishment and Performance Evaluation of a Multiplexed TET2-APOBEC-Mediated cfDNA Methylation Detection Workflow Using qPCR and dPCR Readouts.. J Pers Med. 16(5)
Babor J, Sanchez AM, Prucker I, Jessen HJ, Schwer B, Shuman S.  2026.  How interdiction of inositol pyrophosphate catabolism perturbs the fission yeast response to phosphate starvation.. Nucleic Acids Res. 54(8)
Naylor C, Prosser G, Bayliss T, Berle LF, Wallach JB, Kim H, Olvera RAguilera, Thompson S, Ioerger TR, Simpson L et al..  2026.  Identification and Evaluation of Dibasic Piperidines as Cell Wall Inhibitors against Mycobacterium tuberculosis.. ACS Infect Dis.
Naylor C, Prosser G, Bayliss T, Berle LF, Wallach JB, Kim H, Olvera RAguilera, Thompson S, Ioerger TR, Simpson L et al..  2026.  Identification and Evaluation of Dibasic Piperidines as Cell Wall Inhibitors against Mycobacterium tuberculosis.. ACS Infect Dis.
Naylor C, Prosser G, Bayliss T, Berle LF, Wallach JB, Kim H, Olvera RAguilera, Thompson S, Ioerger TR, Simpson L et al..  2026.  Identification and Evaluation of Dibasic Piperidines as Cell Wall Inhibitors against Mycobacterium tuberculosis.. ACS Infect Dis.
Naylor C, Prosser G, Bayliss T, Berle LF, Wallach JB, Kim H, Olvera RAguilera, Thompson S, Ioerger TR, Simpson L et al..  2026.  Identification and Evaluation of Dibasic Piperidines as Cell Wall Inhibitors against Mycobacterium tuberculosis.. ACS Infect Dis.
Schnappinger D, Berthel SJ, Boshoff HIM, Krieger IV, Sukheja P, Panda S, Rath S, Briggs K, Bian X, Rasheed S et al..  2026.  Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.. EMBO Mol Med.
Schnappinger D, Berthel SJ, Boshoff HIM, Krieger IV, Sukheja P, Panda S, Rath S, Briggs K, Bian X, Rasheed S et al..  2026.  Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.. EMBO Mol Med.
Schnappinger D, Berthel SJ, Boshoff HIM, Krieger IV, Sukheja P, Panda S, Rath S, Briggs K, Bian X, Rasheed S et al..  2026.  Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.. EMBO Mol Med.
Schnappinger D, Berthel SJ, Boshoff HIM, Krieger IV, Sukheja P, Panda S, Rath S, Briggs K, Bian X, Rasheed S et al..  2026.  Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.. EMBO Mol Med.
Pinto AJ, Silva M, Santos JA, VanderVen BC, Monteiro R, Schnappinger D, Ehrt S, Beites T.  2026.  Mycobacterium tuberculosis long-chain fatty acid resistome reveals universal stress protein TB15.3 as essential for infection.. Commun Biol.
Valdambrini E, Kodadek T, Peel M, Barany F.  2026.  Overcoming limitations of targeted protein degraders: developments toward reversible, self-assembling degraders.. Future Med Chem. :1-3.
Klevorn T, Brown C, Hardy CD, Cuthbert BJ, Spencer A, Jinich A, Chan L, Angala SK, Manzer J, Mendoza J et al..  2026.  A periplasmic protein complex mediates arabinofuranosyltransferase activity and intrinsic drug resistance in Mycobacterium tuberculosis.. Sci Adv. 12(14):eaec5100.
Prajapati SK, Dong JX, Morahan BJ, Dotrang T, Barbeau MC, Williams AE, Hupalo D, Wilkerson MD, Dalgard CL, Kafsack BFC et al..  2026.  A single valine to leucine switch disrupts Plasmodium falciparum AP2-G DNA binding and reveals GDV1's role in ap2-g activation.. Nat Commun.
Khonde LPeguy, Peton N, Masike K, Valentine T, Zindo F, Fienberg S, Omollo C, Njoroge M, Vallini F, Tammaro C et al..  2026.  Structure-Activity relationship and optimization of drug-like properties of antituberculosis 3-(4,4-dimethyl-1,4-azasilinane)methylpyrazole MmpL3 inhibitors.. Eur J Med Chem. 312:118841.
Hrach VLee, Schwer B, Vitek L, Borowicz M, Innokentev A, Sanchez AM, Singer JR, Shuman S, Patton-Vogt J.  2026.  Transporter-Driven Glycerophosphocholine (GPC) Toxicity Is Conserved from Fission Yeast to Budding Yeast: Roles for Inositol Pyrophosphates and Gde1 Regulation in Fission Yeast.. Biomolecules. 16(2)
2025
Yang Z, Zhang L, Ottavi S, Geri JB, Perkowski A, Jiang X, Pfau D, Bryk R, Aubé J, Zimmerman M et al..  2025.  ACOD1-mediated lysosomal membrane permeabilization contributes to Mycobacterium tuberculosis-induced macrophage death.. Proc Natl Acad Sci U S A. 122(12):e2425309122.
Du Y, Faz-Lopez B, Kioon MDominique, Cenac C, Pierides M, Lakin KS, Spiera RF, Chaumeil J, Truchetet M-E, Gordon JK et al..  2025.  Altered X-chromosome inactivation of the TLR7/8 locus and heterogeneity of pDCs in systemic sclerosis.. J Exp Med. 222(3)
Smith AA, Su H, Wallach J, Liu Y, Maiello P, H Borish J, Winchell C, Simonson AW, Lin PLing, Rodgers M et al..  2025.  A BCG kill switch strain protects against Mycobacterium tuberculosis in mice and non-human primates with improved safety and immunogenicity.. Nat Microbiol. 10(2):468-481.
Mishra S, Singh PRanjan, Hu X, Lopez-Quezada L, Jinich A, Jahn R, Geurts L, Shen N, DeJesus MA, Hartman T et al..  2025.  Candidate transmission survival genome of Mycobacterium tuberculosis.. Proc Natl Acad Sci U S A. 122(10):e2425981122.
Ames L, Allen R, Boshoff HIM, Cleghorn LAT, Engelhart CA, Schnappinger D, Parish T.  2025.  Common Biological Properties of Mycobacterium tuberculosis MmpL3 Inhibitors.. ACS Infect Dis.
Truong A, Hu R, Quan B, Bailey MA, Schroeder EA, Sylvester K, Neveu G, Kafsack BFC, Fitzgerald MC, Derbyshire ER.  2025.  Covalent inhibition of Plasmodium falciparum Ubc13 impairs global protein synthesis.. iScience. 28(6):112545.